BLACK BIRD BIOTECH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0001 USD | 0.00% |
|
0.00% | 0.00% |
| 16/04 | Black Bird Biotech, Inc. Appoints Nelson Grist as New CEO | CI |
| 16/04 | Black Bird Biotech, Inc. Appoints Nelson Grist as Its Future Member of Its Board of Directors | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 |
|---|---|---|---|
| Capitalization 1 | 7.795 | 6.669 | 0.1882 |
| Enterprise Value (EV) 1 | 7.792 | 6.233 | 0.937 |
| P/E ratio | -8.32 x | -2.42 x | -0.15 x |
| Yield | - | - | - |
| Capitalization / Revenue | 13,53,26,922 x | 6,38,43,296 x | 22,79,205 x |
| EV / Revenue | 13,52,76,804 x | 5,96,67,541 x | 1,13,49,273 x |
| EV / EBITDA | - | -46,46,211 x | -7,81,239 x |
| EV / FCF | -1,17,71,623 x | -2,26,87,488 x | -11,00,44,627 x |
| FCF Yield | -0% | -0% | -0% |
| Price to Book | 286 x | 10.1 x | -0.36 x |
| Nbr of stocks (in thousands) | 1,63,425 | 2,96,397 | 2,50,905 |
| Reference price 2 | 0.0477 | 0.0225 | 0.000750 |
| Announcement Date | 15/04/21 | 15/04/22 | 21/03/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Net sales | - | 0.0178 | 0.0576 | 0.1045 | 0.0826 |
| EBITDA | - | -0.1464 | - | -1.341 | -1.199 |
| EBIT 1 | -0.000138 | -0.1497 | -0.655 | -1.451 | -1.288 |
| Operating Margin | - | -842.23% | -1,137.1% | -1,389.2% | -1,560.42% |
| Earnings before Tax (EBT) 1 | -0.000138 | -0.1494 | -0.6902 | -1.811 | -1.659 |
| Net income 1 | -0.000138 | -0.1494 | -0.6902 | -1.811 | -1.659 |
| Net margin | - | -840.54% | -1,198.11% | -1,734% | -2,009.09% |
| EPS | - | -0.002950 | -0.005734 | -0.009316 | -0.005015 |
| Free Cash Flow | - | - | -0.662 | -0.2747 | -0.008515 |
| FCF margin | - | - | -1,149.18% | -263% | -10.31% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 21/03/19 | 13/07/20 | 15/04/21 | 15/04/22 | 21/03/23 |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 0.75 |
| Net Cash position 1 | 0.04 | 0.11 | 0 | 0.44 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.6243 x |
| Free Cash Flow | - | - | -0.66 | -0.27 | -0.01 |
| ROE (net income / shareholders' equity) | - | -196% | 124% | -519% | -16,555% |
| ROA (Net income/ Total Assets) | - | -119% | -644% | -201% | -162% |
| Assets 1 | - | 0.1253 | 0.1072 | 0.8991 | 1.023 |
| Book Value Per Share 2 | 0 | 0 | 0 | 0 | -0 |
| Cash Flow per Share 2 | 0 | 0 | 0 | 0 | - |
| Capex | - | - | - | 0.01 | - |
| Capex / Sales | - | - | - | 5.46% | - |
| Announcement Date | 21/03/19 | 13/07/20 | 15/04/21 | 15/04/22 | 21/03/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 298K | |
| +40.09% | 6.16B | |
| -16.34% | 4.46B | |
| -7.11% | 3.27B | |
| +5.14% | 3.2B | |
| -0.18% | 2.6B | |
| +47.93% | 1.98B | |
| -7.15% | 1.7B | |
| +0.67% | 1.66B | |
| -8.73% | 1.61B |
- Stock Market
- Equities
- BBBT Stock
- Financials Black Bird Biotech, Inc.